Tirzepatide-Associated Allodynia
Tirzepatide (Mounjaro) has been reported to cause cutaneous allodynia in postmarketing case reports and case series. [1] [2]
Allodynia is not listed as an adverse reaction term in the prescribing information for Mounjaro. [3]
Evidence From Published Clinical Case Reports
A 2026 case series reported moderate-to-severe allodynia temporally associated with tirzepatide dose escalation and resolving after discontinuation in 2 patients treated for weight management. [1]
A 2025 case report described allodynia/dysesthesia occurring with tirzepatide (Mounjaro) and resolving after discontinuation. [2]
Pharmacovigilance Signal
A 2025 FDA Adverse Event Reporting System (FAERS) pharmacovigilance disproportionality analysis identified “allodynia” as one of multiple neurologic adverse event signals associated with GLP-1 receptor agonists, including tirzepatide. [4]
This analysis supports an association signal rather than established causality. [4]
Prescribing Information Concordance
The Mounjaro prescribing information includes hypersensitivity reactions and injection-site reactions in warnings and adverse reactions sections, but it does not list allodynia as a named adverse reaction term. [3]
Clinical Implication
New or worsening cutaneous pain with tactile sensitivity temporally related to tirzepatide initiation or dose escalation is consistent with reported allodynia cases. [1] [2]
Discontinuation was associated with resolution in published cases. [1] [2]
Practical Documentation
Such reactions are appropriate for reporting as suspected adverse reactions. [3]